Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation

Rhea-AI Summary

Pulsenmore (NASDAQ: PLSM) and Clalit Health Services signed a strategic commercial agreement to deploy Pulsenmore FC, an at-home follicular monitoring service, via Beilinson NEXT in Israel. The agreement is potentially valued at $4.5 million over five years following an 18‑month pilot, with ramp-up expected in the coming weeks. Pulsenmore will supply patient‑operated devices, a mobile app with real‑time guidance, and secure image transmission for remote clinical oversight. A June 2025 study at Beilinson reported a strong safety profile and high concordance with in‑clinic measurements. Pulsenmore ES holds FDA De Novo authorization and a separate binding order for 25,000 units was signed in October 2024. Pulsenmore FC is approved for commercial use in Israel.

Positive

• Potential commercial value of $4.5M over five years
• Deployment through Clalit's Beilinson NEXT virtual hospital
• June 2025 study showed strong safety and high concordance
• Existing FDA De Novo clearance for Pulsenmore ES and 25,000‑unit order

Negative

• Agreement contingent on an 18‑month pilot before full value
• Declared value is potential and not guaranteed revenue
• Phase I limited to a small pilot cohort before wider roll‑out

Key Figures

Agreement value: $4.5 million Pilot duration: 18 months Contract term: Five years +3 more

6 metrics

Agreement value $4.5 million Potential value over five years following 18-month pilot with Clalit

Pilot duration 18 months Initial pilot phase before full five-year commercial rollout

Contract term Five years Duration of new Pulsenmore FC commercial agreement with Clalit

ES units ordered 25,000 units Additional Pulsenmore ES units over five years from October 2024 agreement

Share price $5.92 Pre-news price, about 1.89% above 52-week low of $5.81

Market cap $38,887,007 Equity value prior to announcement

Market Reality Check

Price: $6.15 Vol: Volume 25,020 is below th...

normal vol

$6.15 Last Close

Volume Volume 25,020 is below the 20-day average of 31,205, indicating subdued pre-news activity. normal

Technical Shares at 5.92 are trading below the 200-day MA of 6.42 and sit close to the 52-week low of 5.81.

Peers on Argus

No peer stocks were flagged in the momentum scanner and no same-day peer headlin...

No peer stocks were flagged in the momentum scanner and no same-day peer headlines were recorded, suggesting this news is company-specific rather than part of a sector-wide move.

Market Pulse Summary

This announcement highlights a new commercial agreement with Clalit for Pulsenmore FC, potentially w...

Analysis

This announcement highlights a new commercial agreement with Clalit for Pulsenmore FC, potentially worth $4.5 million over five years after an 18-month pilot, and builds on the prior order of 25,000 Pulsenmore ES units. Investors may track adoption within Beilinson NEXT’s virtual hospital, patient uptake of at-home follicular monitoring, and any follow-up data to the June 2025 study demonstrating safety and concordance with in-clinic assessments.

Key Terms

telemedicine

1 terms

telemedicine technical

"By leveraging advanced imaging and telemedicine, Pulsenmore makes care patient-centric"

Telemedicine is the delivery of healthcare services remotely through digital communication tools, such as video calls or online messaging. It allows patients to consult with doctors and medical professionals without visiting a clinic in person. For investors, telemedicine represents a growing sector that combines technology and healthcare, potentially transforming how medical care is accessed and delivered worldwide.

AI-generated analysis. Not financial advice.

Commercial agreement potentially valued at approximately $4.5 million over five years following 18 month pilot;
Service to be deployed via Beilinson NEXT, Beilinson's virtual hospital

RAMAT GAN, Israel, Jan. 26, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a global leader in connected home ultrasound technology, today announced an additional strategic commercial agreement with Clalit Health Services, Israel's largest health maintenance organization (HMO), to supply Pulsenmore FC, a new at-home ultrasound solution designed for remote follicular monitoring in women undergoing fertility care (IVF and fertility preservation). The agreement is potentially valued at approximately $ 4.5 million over five years following an 18 month pilot. The parties expect to begin ramp-up in the coming weeks.

Under the agreement, Pulsenmore and Clalit will establish an end-to-end clinical service operated through Beilinson NEXT, Beilinson Medical Center's virtual hospital, enabling eligible patients to perform follicular monitoring scans from home with real-time online guidance and specialist clinical oversight. The agreement allows both Pulsenmore and Clalit to market Pulsenmore FC directly to patients.

Pulsenmore previously reported results in June 2025 from a controlled clinical study at Beilinson Medical Center that demonstrated a strong safety profile, with high concordance between at-home measurements and in-clinic assessments.  

Fertility treatment often requires frequent in-clinic transvaginal ultrasound scans and repeated visits that disrupt daily life. Pulsenmore FC is designed to offer another way, enabling eligible patients to complete follicular monitoring scans from home using the Pulsenmore FC, a patient-operated ultrasound device, and step-by-step guidance in a mobile app. Scan data are transmitted securely to the Beilinson NEXT care team for remote interpretation and clinical oversight, supporting monitoring of follicle development and endometrial thickness for accurate timing of key moments in treatment, including the trigger injection and egg retrieval, while helping reduce the need for repeated in-clinic visits during IVF and fertility preservation cycles.

"We believe this agreement represents a global breakthrough in how fertility care can be delivered," said Dr. Elazar Sonnenschein, CEO and founder of Pulsenmore. "We are enabling a new model of care that respects patients' time, privacy, and daily lives, while maintaining clinical oversight. We're grateful to Clalit for their  leadership and courage to break new ground for the Beilinson Medical Center and Beilinson NEXT. They are setting a new standard for professional, empathetic, and connected care from home."

Clalit's CEO, Dr. Eytan Wirtheim welcomed the signing of the agreement and the launch of Phase I - the pilot implementation phase for a limited group of women.

According to Wirtheim, "This service fits seamlessly into Clalit's new strategic vision, under which 'Medicine has left the building': any medical service that can be provided to patients from the comfort and calm of their homes, instead of requiring visits to hospital clinics, will be offered in this way as well - provided it can be delivered at the same level of quality as in the hospital setting. I am confident that once we reach the stage of offering this service to the general public, every woman and every couple who will undergo fertility treatments - with all the emotional and physical complexity they entail - will come to appreciate Clalit's new service. For the women and couples who choose to receive the service with us going forward, we will be proud to provide an innovative, world-leading hybrid service that makes life easier, even during the medical process."

Pulsenmore also supplies Clalit with Pulsenmore ES, its physician-supervised home prenatal ultrasound solution, which has recently received FDA De Novo authorization. In October 2024, Pulsenmore signed a binding agreement with Clalit for an additional 25,000 Pulsenmore ES units over five years, supported by Pulsenmore's hardware, secure image transmission, and clinical review workflows across Clalit's care pathways in Israel.

*Pulsenmore FC (follicular monitoring) is approved for commercial use in Israel.

About Pulsenmore

Pulsenmore Ltd. is dedicated to revolutionizing maternal health through the development of home-use ultrasound technology that connects mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com

About Clalit Health Services
Clalit Health Services is Israel's largest health maintenance organization (HMO), serving close to five million members nationwide and operating an integrated network of community-based clinics and hospitals. Clalit is a public, nonprofit organization and owns and operates 14 hospitals alongside a broad national network of primary and specialty care services.

About Beilinson NEXT Virtual Hospital
Beilinson NEXT is Beilinson Medical Center's virtual hospital, built in partnership with Clalit Health Services. Its mission is to deliver advanced, specialist-level care to patients remotely, extending hospital expertise beyond the physical hospital setting to support access, continuity of care, and clinician oversight wherever patients are.

Forward-Looking Statements

This press release contains forward-looking statements. In particular, statements using words such as "may," "seek," "will," "consider," "likely," "assume," "estimate," "expect," "anticipate," "intend," "believe," "contemplate," "do not believe," "aim," "goal," "due," "predict," "plan," "project," "continue," "potential," "positioned," "guidance," "objective," "outlook," "trends," "future," "could," "would," "should," "target," "on track" or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the potential value of the agreement, the market opportunity of Pulsenmore FC and the potential for market growth. Forward-looking statements reflect Pulsenmore's current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company's lack of operating history; the Company's current and future capital requirements and the Company's belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company's ability to manufacture, market and sell its products and to generate revenues; the Company's ability to maintain its relationships with key partners and grow relationships with new partners; the Company's ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company's ability to launch and penetrate markets in new locations and new market segments; the Company's ability to retain key executive members and hire additional personnel; the Company's ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company's ability to achieve greater regulatory compliance needed in existing and new markets; the Company's ability to achieve key performance milestones in its planned operational testing; the Company's ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company's business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company's Form 20-F (SEC File No. 001-43033), filed with the SEC on December 29, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.

Investor Contact:

Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com

Image - https://mma.prnewswire.com/media/2869338/Pulsenmore.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/pulsenmore-and-clalit-health-services-launch-first-at-home-follicular-monitoring-service-for-ivf-and-fertility-preservation-302669979.html

SOURCE Pulsenmore Ltd.

FAQ

What is the value of Pulsenmore's agreement with Clalit (PLSM)?

The agreement is potentially valued at $4.5 million over five years following an 18‑month pilot.

When does Pulsenmore expect to begin ramp‑up of the PLSM service with Clalit?

The parties expect to begin ramp‑up in the coming weeks after the agreement signing on Jan 26, 2026.

What clinical evidence supports Pulsenmore FC for follicular monitoring (PLSM)?

A controlled study at Beilinson in June 2025 reported a strong safety profile and high concordance with in‑clinic scans.

Will Pulsenmore market the at‑home follicular monitoring device directly to patients (PLSM)?

Yes, the agreement allows both Pulsenmore and Clalit to market Pulsenmore FC directly to eligible patients.

Is Pulsenmore FC approved for commercial use in Israel (PLSM)?

Yes, Pulsenmore FC is approved for commercial use in Israel.

How is Pulsenmore integrating clinical oversight into at‑home IVF monitoring (PLSM)?

Scan data are sent securely to the Beilinson NEXT care team for remote interpretation and specialist oversight.